당뇨병 전증 시장 규모, 점유율, 동향 분석 보고서 : 약제 클래스별, 연령층별, 지역별, 부문별 예측(2025-2030년)

Prediabetes Market Size, Share & Trends Analysis Report By Drug Class (Diguanide, Thiazolidinediones, Glucagon-like Peptide-1 Agonists (GLP-1), DPP-4 Inhibitors), By Age Group (Children, Adult, Elderly), By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,242,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,627,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,398,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

당뇨병 전증 시장의 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면 세계 당뇨병 전증 시장 규모는 2030년까지 5억 8,570만 달러에 달할 것으로 예측됩니다.

이 시장은 2025-2030년에 걸쳐 CAGR 10.9%로 성장할 것으로 예상됩니다. 시장 성장의 요인은 여러 가지가 있습니다. 예를 들어, 2023년 6월에 세인트루이스의 워싱턴 대학이 발표한 바에 따르면, 미국에서는 3,700만명 이상이 당뇨병을 앓고 있으며, 그 중 40% 이상이 비만을 경험하고 있습니다. 이 상태는 당뇨병 환자의 최대 절반과 관련이 있습니다. 비만은 종종 앉아서 생활하는 습관과 나쁜 식습관과 관련이 있으며, 당뇨병 전단계 발병의 중요한 위험 요소입니다.

게다가, 유전적 소인이나 가족력도 크게 기여하고 있습니다. 생활 습관이 큰 역할을 하는 한편, 유전적 요인이 개인의 당뇨병 예비군에 대한 감수성에 영향을 주기도 하고, 특정의 집단이 당뇨병 예비군이 되기 쉬워지고 있습니다.

당뇨병 전증 시장 보고서 하이라이트

• 약제 클래스별로는 지구아나이드계가 2024년에 78.8%의 최대 매출 점유율로 시장을 견인했습니다.
• 연령층별로는 성인부문이 2024년에 최대의 매출 점유율로 시장을 선도했습니다.
• 북미는 선진적 의료 인프라, 높은 인지도, 임상 검사를 위한 높은 연구 활동으로 2024년 매출액 점유율 41.3%로 시장을 독점했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 당뇨병 전증 시장의 변수, 동향, 범위

• 시장 계통의 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 비즈니스 환경 분석
  • 산업 분석 - Porter's Five Forces 분석
  • PESTLE 분석

제4장 당뇨병 전증 시장 : 약제 클래스 비즈니스 분석

• 약제 클래스 시장 점유율, 2024년과 2030년
• 약물 클래스 부문 대시보드
• 시장 규모와 예측과 동향 분석, 약제 클래스별, 2018-2030년
• 지구아니드
• 티아졸리딘디온
• 글루카곤 유사 펩티드-1 작용제(GLP-1)
• SGLT2 억제제
• DPP-4 억제제
• 기타

제5장 당뇨병 전증 시장 : 연령층별 비즈니스 분석

• 연령대 시장 점유율, 2024년과 2030년
• 연령대 부문 대시보드
• 시장 규모와 예측과 동향 분석(연령층별, 2018-2030년)
• 유아(12-18세)
• 성인(18-49세)
• 고령자(50세 이상)

제6장 당뇨병 전증 시장 : 지역별, 추정 및 예측 분석

• 지역별 시장 점유율 분석, 2024년과 2030년
• 지역별 시장 대시보드
• 시장 규모와 예측 동향 분석, 2018-2030년
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 노르웨이
  • 스웨덴
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제7장 경쟁 구도

• 참가자 개요
• 기업의 시장 포지셔닝 분석
• 기업 분류
• 전략 매핑
• 기업 프로파일, 상장 기업
  • Novo Nordisk A/S
  • ValbIoTis
  • RESVERLOGIX
  • Caelus Health
  • Scimar
  • Boston Pharmaceuticals
  • APHAIA PHARMA AG
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Pfizer Inc.

SHW

영문 목차

영문목차

Prediabetes Market Growth & Trends:

The global prediabetes market size is anticipated to reach USD 585.7 million by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 10.9% from 2025 to 2030. Several factors drive the market growth. One of the main factors driving is the rising prevalence of prediabetes and increasing obesity rates. Obesity correlates with the development of diabetes. For instance, according to Washington University in St. Louis in June 2023, over 37 million individuals in the U.S. are affected by diabetes, with over 40% of them experiencing obesity, a condition associated with up to half of all diabetes cases. It is estimated that approximately 96 million Americans, constituting roughly one-third of adults, are living with prediabetes. Obesity, often linked with sedentary lifestyles and poor diet, is a significant risk factor for developing prediabetes. The rise in prediabetes cases has coincided with the global obesity epidemic, demonstrating the connection between these two health problems.

Moreover, genetic predisposition and family history also contribute significantly. While lifestyle factors play a predominant role, genetic factors can influence an individual's susceptibility to developing prediabetes, making specific populations more prone to the condition.

Prediabetes Market Report Highlights:

• Based on the drug class, the diguanide segment led the market with the largest revenue share of 78.8% in 2024. Metformin, a drug under the diguanide class is the first choice of drug for the treatment of prediabetes. It is the most commonly prescribed off-label drug for the treatment and slowing down the progression of prediabetes.
• Based on the age group, the adult segment led the market with the largest revenue share in 2024. The increasing sedentary and disease-causing lifestyle among adults is the primary growth factor for this age group segment. The increasing prevalence of prediabetes along with increased awareness are driving the growth of this segment.
• North America dominated the market with the revenue share of 41.3% in 2024, owing to the advanced healthcare infrastructure, high awareness, and high research activities for clinical trials. The region offers an advanced and strong research infrastructure. Community-based programs and support groups empower individuals with prediabetes to make sustainable lifestyle changes, such as healthy eating and regular physical activity.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Class
  • 1.2.2. Age Group
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Prediabetes Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrant
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Prediabetes Market: Drug Class Business Analysis

• 4.1. Drug Class Market Share, 2024 & 2030
• 4.2. Drug Class Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, By Drug Class, 2018 to 2030 (USD Million)
• 4.4. Diguanide
  • 4.4.1. Diguanide Market, 2018 - 2030 (USD Million)
• 4.5. Thiazolidinediones
  • 4.5.1. Thiazolidinediones Market, 2018 - 2030 (USD Million)
• 4.6. Glucagon-like peptide-1 agonists (GLP-1)
  • 4.6.1. Glucagon-like peptide-1 agonists (GLP-1) Market, 2018 - 2030 (USD Million)
• 4.7. SGLT2 inhibitors
  • 4.7.1. SGLT2 inhibitors Market, 2018 - 2030 (USD Million)
• 4.8. DPP-4 inhibitors
  • 4.8.1. DPP-4 inhibitors Market, 2018 - 2030 (USD Million)
• 4.9. Others
  • 4.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Prediabetes Market: Age Group Business Analysis

• 5.1. Age Group Market Share, 2024 & 2030
• 5.2. Age Group Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, By Age Group, 2018 to 2030 (USD Million)
• 5.4. Children (12-18 years)
  • 5.4.1. Children (12-18 years) Market, 2018 - 2030 (USD Million)
• 5.5. Adults (18-49)
  • 5.5.1. Adults (18-49) Market, 2018 - 2030 (USD Million)
• 5.6. Elderly (50+)
  • 5.6.1. Elderly (50+) Market, 2018 - 2030 (USD Million)

Chapter 6. Prediabetes Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030
• 6.4. North America
  • 6.4.1. North America Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. Key Country Dynamic
    • 6.4.2.2. Regulatory Framework
    • 6.4.2.3. Competitive Insights
    • 6.4.2.4. U.S. Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Key Country Dynamic
    • 6.4.3.2. Regulatory Framework
    • 6.4.3.3. Competitive Insights
    • 6.4.3.4. Canada Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1. Key Country Dynamic
    • 6.4.4.2. Regulatory Framework
    • 6.4.4.3. Competitive Insights
    • 6.4.4.4. Mexico Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. Key Country Dynamic
    • 6.5.2.2. Regulatory Framework
    • 6.5.2.3. Competitive Insights
    • 6.5.2.4. UK Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. Germany
    • 6.5.3.1. Key Country Dynamic
    • 6.5.3.2. Regulatory Framework
    • 6.5.3.3. Competitive Insights
    • 6.5.3.4. Germany Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.4. France
    • 6.5.4.1. Key Country Dynamic
    • 6.5.4.2. Regulatory Framework
    • 6.5.4.3. Competitive Insights
    • 6.5.4.4. France Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.5. Italy
    • 6.5.5.1. Key Country Dynamic
    • 6.5.5.2. Regulatory Framework
    • 6.5.5.3. Competitive Insights
    • 6.5.5.4. Italy Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.6. Spain
    • 6.5.6.1. Key Country Dynamic
    • 6.5.6.2. Regulatory Framework
    • 6.5.6.3. Competitive Insights
    • 6.5.6.4. Spain Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.7. Denmark
    • 6.5.7.1. Key Country Dynamic
    • 6.5.7.2. Regulatory Framework
    • 6.5.7.3. Competitive Insights
    • 6.5.7.4. Denmark Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.8. Norway
    • 6.5.8.1. Key Country Dynamic
    • 6.5.8.2. Regulatory Framework
    • 6.5.8.3. Competitive Insights
    • 6.5.8.4. Norway Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.9. Sweden
    • 6.5.9.1. Key Country Dynamic
    • 6.5.9.2. Regulatory Framework
    • 6.5.9.3. Competitive Insights
    • 6.5.9.4. Sweden Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key Country Dynamic
    • 6.6.2.2. Regulatory Framework
    • 6.6.2.3. Competitive Insights
    • 6.6.2.4. Japan Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key Country Dynamic
    • 6.6.3.2. Regulatory Framework
    • 6.6.3.3. Competitive Insights
    • 6.6.3.4. China Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key Country Dynamic
    • 6.6.4.2. Regulatory Framework
    • 6.6.4.3. Competitive Insights
    • 6.6.4.4. India Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.5. South Korea
    • 6.6.5.1. Key Country Dynamic
    • 6.6.5.2. Regulatory Framework
    • 6.6.5.3. Competitive Insights
    • 6.6.5.4. South Korea Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.6. Australia
    • 6.6.6.1. Key Country Dynamic
    • 6.6.6.2. Regulatory Framework
    • 6.6.6.3. Competitive Insights
    • 6.6.6.4. Australia Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.7. Thailand
    • 6.6.7.1. Key Country Dynamic
    • 6.6.7.2. Regulatory Framework
    • 6.6.7.3. Competitive Insights
    • 6.6.7.4. Thailand Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamic
    • 6.7.2.2. Regulatory Framework
    • 6.7.2.3. Competitive Insights
    • 6.7.2.4. Brazil Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamic
    • 6.7.3.2. Regulatory Framework
    • 6.7.3.3. Competitive Insights
    • 6.7.3.4. Argentina Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.8. Middle East and Africa
  • 6.8.1. Middle East and Africa Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamic
    • 6.8.2.2. Regulatory Framework
    • 6.8.2.3. Competitive Insights
    • 6.8.2.4. South Africa Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamic
    • 6.8.3.2. Regulatory Framework
    • 6.8.3.3. Competitive Insights
    • 6.8.3.4. Saudi Arabia Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamic
    • 6.8.4.2. Regulatory Framework
    • 6.8.4.3. Competitive Insights
    • 6.8.4.4. UAE Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamic
    • 6.8.5.2. Regulatory Framework
    • 6.8.5.3. Competitive Insights
    • 6.8.5.4. Kuwait Prediabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. Novo Nordisk A/S
    • 7.5.1.1. Participant's Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Valbiotis
    • 7.5.2.1. Participant's Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. RESVERLOGIX
    • 7.5.3.1. Participant's Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. Caelus Health
    • 7.5.4.1. Participant's Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. Scimar
    • 7.5.5.1. Participant's Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. Boston Pharmaceuticals
    • 7.5.6.1. Participant's Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. APHAIA PHARMA AG
    • 7.5.7.1. Participant's Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. AstraZeneca
    • 7.5.8.1. Participant's Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. Bristol-Myers Squibb Company
    • 7.5.9.1. Participant's overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic Initiatives
  • 7.5.10. Pfizer Inc.
    • 7.5.10.1. Participant's Overview
    • 7.5.10.2. Financial Performance
    • 7.5.10.3. Product Benchmarking
    • 7.5.10.4. Strategic Initiatives

관련자료